摘要
目的 :探讨CD44V6及C erbB 2表达与非小细胞肺癌临床病理特征之间的关系。方法 :采用S P免疫组化法检测 132例非小细胞肺癌、6 6例淋巴结转移癌、95例癌旁肺组织和 2 0例正常肺组织CD44V6和C erbB 2表达的情况。结果 :非小细胞肺癌CD44V6阳性表达率为 48 4 8%,明显高于癌旁肺组织 16 84%和正常肺组织 2 0 0 0 %的阳性有效率。CD44V6阳性表达与淋巴结转移状况、TNM分期、肿瘤大小和组织学类型有显著相关性。非小细胞肺癌淋巴结转移组、TNMⅢ期患者、直径>3cm的肿瘤和鳞癌CD44V6阳性表达率分别明显高于无淋巴结转移组、TNMⅠ、Ⅱ期患者、直径≤ 3cm的肿瘤和腺癌。淋巴结转移癌CD44V6阳性表达率明显高于肺原发癌。CD44V6阳性表达与患者的性别、年龄和组织学分级无显著相关性。非小细胞肺癌C erbB 2阳性表达率为 6 1 36 %,明显高于癌旁肺组织 18 95 %和正常肺组织 10 0 0 %的阳性表达率。C erbB 2阳性表达与临床病理特征无显著相关性。结论 :CD44V6阳性表达预示非小细胞肺癌具有较强的侵袭和转移能力 ,CD44V6可作为一项预测非小细胞肺癌转移潜能及判断预后的生物学指标。C erbB
Objective:To investigate the relationship between CD44V6 and C-erbB-2 expression and clinicpathologic characteristics in non-small cell lung carcinomas(NSCLC).Methods:CD44V6 and C-erbB-2 protein was detected by S-P immunohistochemical method in 132 cases of NSCLC, 66 cases of metastatic lymph nodes, 95 cases of paracancer lung tissue and 20 cases of normal lung tissue.Results:CD44V6 positive expression of NSCLC was 48.48%, significantly higher than that of paracancer lung tissue(16.84%) and normal lung tissue(20.00%). CD44V6 positive expression was significant correlation with lymph nodes status, TNM stage, tumor size and histological type, but was not significant correlation with the patients sex, age, and histological grade. CD44V6 positive expression in NSCLC with lymph node metastasis, TNM stage Ⅲ,tumor >3cm diameter and squamous cell carcinomas was significantly higher than that without lymph node metastasis, TNM stage Ⅰ,Ⅱ, tumor ≤3cm diameter and adenocarcinomas. CD44V6 positive expression of metastatic lymph nodes was significantly higher than that of primary lung carcinomas. C-erbB-2 positive expression of NSCLC was 61.36%, significantly higher than that of paracancer lung tissue (18.95%) and normal lung tissue (10.00%).C-erbB-2 positive expression was not significant correlation with clinicopathologic characteristics.Conclusion:CD44V6 positive expression indicated that NSCLC has stronger invasion and metastasis potential. CD44V6 is a useful marker of predicting the metastatic potential and the prognosis of NSCLC. C-erbB-2 is not an useful marker for predicting the prognosis of NSCLC.
出处
《临床肿瘤学杂志》
CAS
2003年第4期257-260,共4页
Chinese Clinical Oncology